^
    Back
    Association details:
    Biomarker:CD44 expression
    Cancer:Renal Cell Carcinoma
    Drug:sunitinib (c-KIT inhibitor, VEGFR inhibitor, PDGFR inhibitor)
    Direction:Resistant
    Evidence:
    Evidence Level:
    Resistant: C3 – Early Trials
    New
    Source:
    Anticancer Res
    Title:

    CD44 Is Involved in Sunitinib Resistance and Poor Progression-free Survival After Sunitinib Treatment of Renal Cell Carcinoma

    Excerpt:
    CD44 expression in mRCC patients treated with first-line sunitinib was determined by immunohistochemistry….CD44-positive cases were associated with poor progression-free survival (PFS) after first-line sunitinib treatment.
    DOI:
    10.21873/anticanres.15301